EQL Pharma Balance Sheet Health
Financial Health criteria checks 3/6
EQL Pharma has a total shareholder equity of SEK177.7M and total debt of SEK117.7M, which brings its debt-to-equity ratio to 66.2%. Its total assets and total liabilities are SEK373.8M and SEK196.0M respectively. EQL Pharma's EBIT is SEK32.6M making its interest coverage ratio 5.9. It has cash and short-term investments of SEK20.5M.
Key information
66.2%
Debt to equity ratio
SEK 117.67m
Debt
Interest coverage ratio | 5.9x |
Cash | SEK 20.47m |
Equity | SEK 177.73m |
Total liabilities | SEK 196.03m |
Total assets | SEK 373.76m |
Recent financial health updates
Recent updates
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
Jun 13EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
May 14EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?
Jun 29Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns
Jun 07If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late
Apr 16How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 03What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation
Jan 16Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?
Dec 28What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?
Dec 11EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment
Nov 22Financial Position Analysis
Short Term Liabilities: EQL's short term assets (SEK197.8M) exceed its short term liabilities (SEK162.1M).
Long Term Liabilities: EQL's short term assets (SEK197.8M) exceed its long term liabilities (SEK34.0M).
Debt to Equity History and Analysis
Debt Level: EQL's net debt to equity ratio (54.7%) is considered high.
Reducing Debt: EQL's debt to equity ratio has increased from 14% to 66.2% over the past 5 years.
Debt Coverage: EQL's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: EQL's interest payments on its debt are well covered by EBIT (5.9x coverage).